Used primarily as a key intermediate in the synthesis of targeted protein degradation therapeutics, particularly in the development of cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, facilitating the ubiquitination and subsequent degradation of disease-related proteins. This makes it valuable in creating compounds for treating cancers, especially hematological malignancies like multiple myeloma and myelodysplastic syndromes. It is also employed in research to design PROTACs (proteolysis-targeting chimeras), where its bromo group allows for further functionalization via cross-coupling reactions. Its application extends to medicinal chemistry for optimizing drug candidates with improved potency and selectivity.